Completion of Inspection of Plant
Marksans Pharma Ltd has informed BSE that the Company's plant located at L-82 & L-83, Verna Industrial Estate, Verna, Goa - 403 722 has had an inspection by UK MHRA from February 14, 2017 to February 17, 2017. The same has been completed without any critical observations.The Company is awaiting further instruction from the agency in this regard. Losing ground in Q3: Income and profits fall at Marksans Pharma
Marksans Pharma announced a fall in income in Q3 by 1.0% to Rs. 215.2 crore, a decline compared to the same quarter the previous year. Net profits also fell this quarter compared to last year's quarter, declining by over 31% to Rs. 12.8 crore. This is a sharp reversal from the momentum the company had seen in the past year. The company is struggling with competition and price cuts in the UK and Europe markets, where revenues declined by over 35% in the nine months of FY17 compared to the previous year. Marksans Pharma is likely to now end FY17 with lower profits compared to FY16. Results Press Release for December 31, 2016
Marksans Pharma Ltd has informed BSE about : 1. Result Press Release for the period ended December 31, 2016 Announces Q3 results (Standalone & Consolidated) & Limited Review Report (Standalone & Consolidated) for the Quarter ended December 31, 2016
Marksans Pharma Ltd has announced the following results for the quarter ended December 31, 2016:The Unaudited Standalone results for the Quarter ended December 31, 2016The Company has posted a net profit of Rs. 84.39 million for the quarter ended December 31, 2016 as compared to Rs. 139.88 million for the quarter ended December 31, 2015. Total Income has decreased from Rs. 692.95 million for the quarter ended December 31, 2015 to... Q3 results on Feb 06, 2017
Marksans Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on February 06, 2017, inter alia, to consider and approve Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Third Quarter ended on December 31, 2016 (Q3).Further, as per the Insider Trading Policy of the Company, Trading Window for dealing in Companys shares will remain closed for the Companys Insiders... Shareholding for the Period Ended December 31, 2016
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Marksans Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Results Press Release for September 30, 2016
Marksans Pharma Ltd has informed BSE about : 1. Result Press Release for the period ended September 30, 2016 Announces Q2 results (Standalone & Consolidated) & Limited Review Report (Standalone & Consolidated) for the Quarter ended September 30, 2016
Marksans Pharma Ltd has announced the following results for the quarter ended September 30, 2016:The Unaudited Standalone results for the Quarter ended September 30, 2016The Company has posted a net profit of Rs. 25.68 million for the quarter ended September 30, 2016 as compared to Rs. 285.37 million for the quarter ended September 30, 2015. Total Income has decreased from Rs. 1170.84 million for the quarter ended September 30, 2015... Q2 results on Nov 12, 2016
Marksans Pharma Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 12, 2016, inter alia, to consider and approve Unaudited Financial Results of the Company (both Standalone and Consolidated) for the Second Quarter ended on September 30, 2016 (Q2).Further, as per the Insider Trading Policy of the Company, Trading Window for dealing in Companys shares will remain closed for the Companys Insiders...